In 2008, the Food and Drug Administration (FDA) mandated that new medications for type 2 diabetes mellitus (T2DM) must undergo cardiovascular (CV) outcomes trials, given the association of CV risk with some anti-hyperglycemic agents. Over the last 5 years, CV outcomes trials that demonstrated CV benefit for several SGLT2 inhibitors and GLP-1 RAs have been published, resulting in a flurry of new CV indications for these agents. The discovery that SGLT2 inhibitors and GLP-1 RAs may reduce the risk of adverse CV events in T2DM has caused a major paradigm shift, in which comprehensive CV risk reduction now plays a central role in the management of T2DM. Consequently, the American College of Cardiology (ACC) and the American Diabetes Association (ADA) have issued a position statement and updated guideline recommendations, respectively, that provide guidance on the use of SGLT2 inhibitors and GLP-1 RAs to reduce the risk of CV events in patients with T2DM. Primary care providers (PCPs) frequently treat patients with T2DM and play a crucial role in the management of their disease. As a result, PCPs need to be familiar with the SGLT2 inhibitors and GLP-1 RAs that have demonstrated CV benefit in T2DM, as well as the efficacy and safety data for these agents from CV outcomes trials in T2DM. Given the large volume of evidence, however, PCPs may be challenged to translate clinical trial results into clinical practice. Based on a review of the literature and an interview with a diabetes expert, we have identified knowledge and practice gaps among PCPs regarding the use of novel anti-hyperglycemic agents with proven CV benefit in patients with T2DM that will be addressed in the current proposal. To address these identified gaps, JHU, in collaboration with Medical Logix, is proposing to develop a multi-modal program, leveraging educational platforms that maximize audience engagement and have a proven track record of generating positive outcomes. These platforms include two online activities via the Clinical Dialogue and eCase Challenge program. Through the combination of didactic and case-based platforms, this program will appeal to various learning styles and allow participants to reinforce their knowledge and acquire new skills that can immediately be applied to clinical practice. Each activity applies proven educational strategies that promote a positive impact on both learning and behavior. These strategies integrate basic principles of adult learning that include self-assessment, reflection and reinforcement of new knowledge and behaviors.

Please click on this link to the CME activity: https://medical-logix.com/JHU/UI/MedicalLogix.aspx?WorkShopId=123&UserType=34

Note:  Once you have completed the CME activity, you will be prompted back to this site to complete the post-test and evaluation.

1. Summarize the efficacy data for SGLT2 inhibitors and GLP-1 RAs in cardiovascular outcomes trials in type 2 diabetes.
2. Discuss the adverse events associated with SGLT2 inhibitors and GLP-1 RAs with proven cardiovascular benefit in type 2 diabetes.
3. Identify patients with type 2 diabetes who may benefit from an SGLT2 inhibitor or GLP-1 RA with proven cardiovascular benefit.
4. Select the appropriate SGLT2 inhibitor or GLP-1 RA to reduce the risk of cardiovascular events in patients with type 2 diabetes based on individual patient factors.